ImmunSYS, Inc. Presents at the BIO International Convention
FORT LAUDERDALE, FL–June 6, 2019–ImmunSYS, Inc. announced today that Chairman & CEO Eamonn Hobbs presented on June 3rd at the 2019 BIO International Conference, held at the Pennsylvania Convention Center in Philadelphia. BIO 2019 featured over 17,000 attendees, more than 8400 companies, over 250 company presentations, and 126 educational sessions. Prostate cancer treatment, in particular, …
ImmunSYS, Inc. Presents at the BIO International Convention Read More »
ImmunSYS Presents at the 2020 BIO CEO & Investor Conference
FORT LAUDERDALE, FL – FEBRUARY 13, 2020 – ImmunSYS announced today that Charles Link, M.D., President and Chief Medical Officer, presented this week on February 11th at the 2020 BIO CEO & Investor Conference in New York. Now in its 22nd year, the conference is one of the largest independent investor conferences focused on established and …
ImmunSYS Presents at the 2020 BIO CEO & Investor Conference Read More »
June is Cancer Immunotherapy Month
Immunotherapy is considered to be one of the most promising therapies in the effort to cure cancer. It works by enhancing the body’s own immune system, enabling the immune system to recognize, target, and eliminate cancer cells. Recent groundbreaking research has produced an increasing number of cancer-fighting therapies that harness the immune system in different …
ImmunSYS Announces Upcoming Presentation at AACR Virtual Annual Meeting II
FORT LAUDERDALE, Florida, May 15, 2020 — (BUSINESS WIRE) — ImmunSYS, Inc., a clinical- stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that results from a proof of concept (PoC) study evaluating its proprietary immunotherapy platform, YourVaccx™, for the treatment of patients with metastatic solid tumor cancers will be …
ImmunSYS Announces Upcoming Presentation at AACR Virtual Annual Meeting II Read More »
ImmunSYS Welcomes George C. Prendergast, PhD, a Renowned
Cancer Immunology Expert, to its Scientific Advisory Board
FORT LAUDERDALE, Florida, June 11, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, announced today the appointment of George C. Prendergast, PhD, a leading researcher and pioneer in immune therapies, to their scientific advisory board, effective April 2020. “We are honored to welcome Dr. Prendergast to …
50% Complete Response Rate Observed in YourVaccx™ Study for Patients with Metastatic Prostate Cancer was Presented at the AACR Virtual Annual Meeting II
– In 18 evaluable patients with metastatic prostate cancer, 50% had a Complete Response (CR) and 62% had post-therapy PSA reductions of ≥ 50%– FORT LAUDERDALE, Florida, June 22, 2020 — (BUSINESS WIRE) — ImmunSYS, Inc., a clinical stage biopharmaceutical company focused on the …
ImmunSYS Announces it Hosted a Virtual Analyst Day Event on July 7, 2020
FORT LAUDERDALE, Florida, July 13, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020. Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President …
ImmunSYS Announces it Hosted a Virtual Analyst Day Event on July 7, 2020 Read More »
Replay of Discussion of Proof of Concept (PoC) Study Data Presented at AACR
Click here to see a replay of a company business overview by ImmunSYS executives along with a discussion by key opinion leaders of the current prostate cancer landscape and a review the Proof of Concept (PoC) data presented in June at the 2020 AACR Virtual Annual Meeting II
Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series
Presented at the 2020 AACRVirtual Annual Meeting II View Pdf
